Showing results (11-20 of 2,432) with videos related to
Sort By:
Pageof 244
Pharmacology, Biochemistry, and Behavior|April 12, 2005
The role of the phosphatidyinositol-linked D1 dopamine receptor in the pharmacology of SKF83959Xuechu Zhen, Satindra Goswami, Eitan FriedmanACS Chemical Neuroscience|September 11, 2018
Development of Adenosine AJiyue Zheng, Xiaohu Zhang, Xuechu ZhenNeuroscience Letters|September 3, 2003
Prenatal cocaine exposure alters glycogen synthase kinase-3beta (GSK3beta) pathway in select rabbit brain areasMara Gil, Xuechu Zhen, Eitan FriedmanJournal of Medicinal Chemistry|May 20, 2011
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profileHai Zhang, Na Ye, Shanglin Zhou, et al.Biomolecules|September 28, 2024
'Whole-Body' Perspectives of Schizophrenia and Related Psychotic Illness: miRNA-143 as an Exemplary Molecule Implicated across Multi-System DysfunctionsJohn L Waddington, Xiaoyu Wang, Xuechu ZhenMolecular Pharmacology|November 19, 2002
Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson's diseaseXuechu Zhen, Claudio Torres, Guoping Cai, et al.Medicinal Research Reviews|July 22, 2008
Dopamine D1 receptor ligands: where are we now and where are we goingJing Zhang, Bing Xiong, Xuechu Zhen, et al.Cellular and Molecular Neurobiology|August 22, 2007
Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addictionHongyuan Chu, Guozhang Jin, Eitan Friedman, et al.Medicinal Research Reviews|September 20, 2024
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunitiesNa Ye, Qi Wang, Yue Li, et al.Current Neuropharmacology|September 29, 2015
Neuropharmacological Actions of Metformin in StrokeJia Jia, Jian Cheng, Jingshu Ni, et al.Pageof 244